医学
癌症研究
NF-κB
癌症
疾病
下调和上调
头颈部癌
头颈部鳞状细胞癌
转录因子
放射治疗
头颈部
肿瘤科
内科学
生物
基因
炎症
外科
生物化学
作者
Javadi Monisha,Nand Kishor Roy,Devivasha Bordoloi,Amit Kumar,Ramesh Golla,Jibon Kotoky,Ganesan Padmavathi,Ajaikumar B. Kunnumakkara
出处
期刊:Current Drug Targets
[Bentham Science]
日期:2016-12-29
卷期号:18 (2): 232-253
被引量:41
标识
DOI:10.2174/1389450117666160201112330
摘要
Despite the consistent and significant advancements made in the treatment of head and neck cancer (HNSCC), it remains one of the most devastating cancers globally killing approximately 350,000 people every year. Both clinical and basic research revealed that the transcription factor NF-κB, is constitutively expressed in HNSCC and this persistent expression of NF-κB is the root cause of this disease resulting in cancer cell proliferation, survival, invasion, metastases and poor survival of patients. Activation of NF-κB is pragmatic in most of the premalignant dysplastic lesions indicating it as an early episode in malignant transformation of this disease. Therefore, therapies designed to inhibit or block the activity of NF-κB, would result in downregulation of key cellular processes involved in tumor growth and its dissemination to metastatic sites. In addition, substantial evidences have revealed that NF-κB plays an indispensable role in the development of both chemo and radiation resistance in HNSCC which is identified to be a primary cause for the failure of therapies. This shows the potential of targeting NF- κB in developing therapies against this disease. This review summarises the role of NF-κB in the development of HNSCC and the potential of using NF-κB as a target to develop novel highly effective therapies for this disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI